Clinical and angiographic results with the NIR stent: First International NIR Endovascular Stent Study (FINESS-II)
- 1 January 2000
- journal article
- research article
- Published by Taylor & Francis in International Journal of Cardiovascular Interventions
- Vol. 3 (3), 143-151
- https://doi.org/10.1080/14628840050516055
Abstract
BACKGROUND: Although safety and efficacy of the NIR ™ stent have been reported, the long-term angiographic and clinical outcomes have yet to be investigated. The FINESS-II study (First International NIR Endovascular Stent Study) was designed to assess the procedural safety of single 9 and 16 mm NIR stent implantation, the six-month restenosis rate and finally the six- and 12-month clinical outcome of patients treated with this novel coronary stent. METHODS: Patients with angina and a single de novo lesion in a native coronary artery of >3 and 50% diameter stenosis criterion at six month follow-up was 19% (26/136). At 12 months, the event-free survival rate was 83% (two deaths, one Q-wave and three non-Q-wave myocardial infarctions, four bypass surgery and 17 target lesion revascularizations), while 87% of the patients were free of angina pectoris. CONCLUSION: the outcome of the FINESS-II trial is comparable to those observed in previous stent trials (Benestent II), indicating that the coronary NIR stent is safe and effective as a primary device for the treatment of native coronary artery endpoints. lesions in patients with (un)stable angina pectoris. (Int J Cardiovasc Intervent 2000; 3: 143–151)Keywords
This publication has 12 references indexed in Scilit:
- Clinical and angiographic results with the beStent: the Registry for Optimal beStent Evaluation (ROSE) trialInternational Journal of Cardiovascular Interventions, 2000
- Plant lipids that lower serum cholesterolPublished by Oxford University Press (OUP) ,1999
- Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six monthsJournal of the American College of Cardiology, 1999
- Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)The Lancet, 1998
- First International New Intravascular Rigid-Flex Endovascular Stent Study (FINESS): Clinical and Angiographic Results After Elective and Urgent Stent ImplantationJournal of the American College of Cardiology, 1997
- Heparin-Coated Palmaz-Schatz Stents in Human Coronary ArteriesCirculation, 1996
- Coronary intervention: Risk stratification and management of abrupt coronary occlusionEuropean Heart Journal, 1995
- Effect of high dose angiotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazaprilJournal of the American College of Cardiology, 1995
- Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.Circulation, 1992
- Importance of stenosis morphology in the estimation of restenosis risk after elective percutaneous transluminal coronary angioplastyThe American Journal of Cardiology, 1989